XARELTO
PeakNDAORALTABLET
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1945
Data completeness
3/8 — Basic
IRA Negotiated
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARELTO is an oral small-molecule anticoagulant tablet approved by the FDA on November 4, 2011, and currently at peak market lifecycle stage. The drug is indicated for thromboembolic prevention and treatment, operating as a Factor Xa inhibitor to reduce clot formation. As a direct oral anticoagulant (DOAC), it represents a major advance over warfarin-based therapy, offering predictable pharmacokinetics and no requirement for routine monitoring.
$6.3BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1945)
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
Started Dec 2026
2,500 enrolled
Atrial FibrillationStroke
REal World MAIA UK OutcomEs
Started Jul 2026
300 enrolled
Myeloma
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
Started Jul 2026
50 enrolled
Multiple Myeloma (MM)
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Started Jun 2026
700 enrolled
Multiple Myeloma
Bumetanide vs. Furosemide in Cirrhosis
Started May 2026
500 enrolled
Cirrhosis
Worked on XARELTO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.